CA2193543A1 - Sodium hyaluronate based ophthalmic formulation for use in eye surgery - Google Patents

Sodium hyaluronate based ophthalmic formulation for use in eye surgery

Info

Publication number
CA2193543A1
CA2193543A1 CA002193543A CA2193543A CA2193543A1 CA 2193543 A1 CA2193543 A1 CA 2193543A1 CA 002193543 A CA002193543 A CA 002193543A CA 2193543 A CA2193543 A CA 2193543A CA 2193543 A1 CA2193543 A1 CA 2193543A1
Authority
CA
Canada
Prior art keywords
sodium hyaluronate
eye surgery
ophthalmic formulation
based ophthalmic
hyaluronate based
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA002193543A
Other languages
French (fr)
Other versions
CA2193543C (en
Inventor
Rene-Pierre Bunter
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Chemedica SA
Original Assignee
Chemedica SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chemedica SA filed Critical Chemedica SA
Publication of CA2193543A1 publication Critical patent/CA2193543A1/en
Application granted granted Critical
Publication of CA2193543C publication Critical patent/CA2193543C/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution

Abstract

The present invention relates to an ophthalmic formulation, for use in eye surgery, comprising sodium hyaluronate, citrate, at least one antioxidant tolerated by the intraocular tissues and a phosphate buffer.
CA002193543A 1995-12-22 1996-12-20 Sodium hyaluronate based ophthalmic formulation for use in eye surgery Expired - Lifetime CA2193543C (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IT95MI002744A IT1277707B1 (en) 1995-12-22 1995-12-22 OPHTHALMIC FORMULATION BASED ON SODIUM HYALURONATE FOR USE IN OCULAR SURGERY
ITMI95A002744 1995-12-22

Publications (2)

Publication Number Publication Date
CA2193543A1 true CA2193543A1 (en) 1997-06-23
CA2193543C CA2193543C (en) 2006-02-21

Family

ID=11372809

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002193543A Expired - Lifetime CA2193543C (en) 1995-12-22 1996-12-20 Sodium hyaluronate based ophthalmic formulation for use in eye surgery

Country Status (10)

Country Link
US (1) US5880107A (en)
EP (1) EP0781547B1 (en)
JP (1) JP4146910B2 (en)
AT (1) ATE216221T1 (en)
CA (1) CA2193543C (en)
DE (1) DE69620724T2 (en)
DK (1) DK0781547T3 (en)
ES (1) ES2175020T3 (en)
IT (1) IT1277707B1 (en)
PT (1) PT781547E (en)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6541460B2 (en) 1996-08-07 2003-04-01 George D. Petito Method for use of hyaluronic acid in wound management
US6368585B1 (en) * 1997-03-25 2002-04-09 Pharmacia Ab Opthalmic compositions and methods
US20030138499A1 (en) * 1998-12-17 2003-07-24 Shah Mandar V. Stable surgical irrigating solutions
US6533769B2 (en) * 2001-05-03 2003-03-18 Holmen Joergen Method for use in cataract surgery
US7820194B2 (en) 2001-12-21 2010-10-26 Alcon, Inc. Combinations of viscoelastics for use during surgery
ITMI20020557A1 (en) * 2002-03-15 2003-09-15 Acraf USE OF A SALT OF L-ASCORBIC ACID TO PREPARE A PHARMACEUTICAL COMPOSITION FOR TOPICAL OPHTHALMIC USE CAPABLE OF IMPROVING THE LEVEL D
US20040167480A1 (en) * 2003-02-21 2004-08-26 Advanced Medical Optics, Inc. Administration of multiple viscoelastic solutions with a multi-compartment syringe
FR2861734B1 (en) 2003-04-10 2006-04-14 Corneal Ind CROSSLINKING OF LOW AND HIGH MOLECULAR MASS POLYSACCHARIDES; PREPARATION OF INJECTABLE SINGLE PHASE HYDROGELS; POLYSACCHARIDES AND HYDROGELS OBTAINED
US20050215516A1 (en) * 2004-03-29 2005-09-29 Claudio Bucolo New free-radical scavenger containing viscoelastic composition, methods of use and package
US20060073184A1 (en) * 2004-09-29 2006-04-06 Bausch & Lomb Inc. Viscoelastic composition, methods of use and packaging device with anti-oxidant
WO2008042441A1 (en) * 2006-10-03 2008-04-10 Anthrogenesis Corporation Use of umbilical cord biomaterial for ocular surgery
CA2687990A1 (en) * 2007-05-23 2008-12-04 Allergan, Inc. Cross-linked collagen and uses thereof
US8318695B2 (en) * 2007-07-30 2012-11-27 Allergan, Inc. Tunably crosslinked polysaccharide compositions
US8697044B2 (en) 2007-10-09 2014-04-15 Allergan, Inc. Crossed-linked hyaluronic acid and collagen and uses thereof
EP3498299A1 (en) 2007-11-16 2019-06-19 Aclaris Therapeutics, Inc. Compositions and methods for treating purpura
US8394784B2 (en) * 2007-11-30 2013-03-12 Allergan, Inc. Polysaccharide gel formulation having multi-stage bioactive agent delivery
US8394782B2 (en) * 2007-11-30 2013-03-12 Allergan, Inc. Polysaccharide gel formulation having increased longevity
US20090143348A1 (en) * 2007-11-30 2009-06-04 Ahmet Tezel Polysaccharide gel compositions and methods for sustained delivery of drugs
WO2009084044A1 (en) * 2007-12-27 2009-07-09 D.M.G. Italia Srl Composition comprising superoxide dismutase and carboxv methyl beta-1,3 glucan
US8357795B2 (en) 2008-08-04 2013-01-22 Allergan, Inc. Hyaluronic acid-based gels including lidocaine
EP3184552B1 (en) 2008-09-02 2020-08-12 Tautona Group LP Threads of hyaluronic acid, methods of making thereof and uses thereof
US20100104654A1 (en) * 2008-10-27 2010-04-29 Allergan, Inc. Prostaglandin and prostamide drug delivery systems and intraocular therapeutic uses thereof
JP4885245B2 (en) * 2009-01-15 2012-02-29 日本航空電子工業株式会社 RD converter and angle detection device
JP2013513622A (en) * 2009-12-14 2013-04-22 ユニバーシティ オブ マサチューセッツ Methods for inhibiting cataracts and presbyopia
US20110171311A1 (en) * 2010-01-13 2011-07-14 Allergan Industrie, Sas Stable hydrogel compositions including additives
US9114188B2 (en) 2010-01-13 2015-08-25 Allergan, Industrie, S.A.S. Stable hydrogel compositions including additives
US20110171310A1 (en) * 2010-01-13 2011-07-14 Allergan Industrie, Sas Hydrogel compositions comprising vasoconstricting and anti-hemorrhagic agents for dermatological use
US20110172180A1 (en) 2010-01-13 2011-07-14 Allergan Industrie. Sas Heat stable hyaluronic acid compositions for dermatological use
CA2792729C (en) 2010-03-12 2016-06-28 Allergan Industrie, Sas Fluid compositions for improving skin conditions
CA2794254C (en) 2010-03-22 2018-09-04 Allergan, Inc. Polysaccharide and protein-polysaccharide cross-linked hydrogels for soft tissue augmentation
US8883139B2 (en) 2010-08-19 2014-11-11 Allergan Inc. Compositions and soft tissue replacement methods
US8889123B2 (en) 2010-08-19 2014-11-18 Allergan, Inc. Compositions and soft tissue replacement methods
US9005605B2 (en) 2010-08-19 2015-04-14 Allergan, Inc. Compositions and soft tissue replacement methods
US8697057B2 (en) 2010-08-19 2014-04-15 Allergan, Inc. Compositions and soft tissue replacement methods
US20130096081A1 (en) 2011-06-03 2013-04-18 Allergan, Inc. Dermal filler compositions
US9408797B2 (en) 2011-06-03 2016-08-09 Allergan, Inc. Dermal filler compositions for fine line treatment
US9393263B2 (en) 2011-06-03 2016-07-19 Allergan, Inc. Dermal filler compositions including antioxidants
US9149422B2 (en) 2011-06-03 2015-10-06 Allergan, Inc. Dermal filler compositions including antioxidants
US9662422B2 (en) 2011-09-06 2017-05-30 Allergan, Inc. Crosslinked hyaluronic acid-collagen gels for improving tissue graft viability and soft tissue augmentation
US20130244943A1 (en) 2011-09-06 2013-09-19 Allergan, Inc. Hyaluronic acid-collagen matrices for dermal filling and volumizing applications
NZ708821A (en) * 2012-12-19 2020-03-27 Novartis Ag Lfa-1 inhibitor formulations
AT514540A1 (en) * 2013-06-18 2015-01-15 Apomedica Pharmazeutische Produkte Gmbh Ophthalmic composition
PL3019177T3 (en) * 2013-07-10 2021-04-19 Matrix Biology Institute Compositions of hyaluronan with high elasticity and uses thereof
WO2015125921A1 (en) * 2014-02-20 2015-08-27 わかもと製薬株式会社 Medical aqueous composition having preservative effectiveness
WO2016051219A1 (en) 2014-09-30 2016-04-07 Allergan Industrie, Sas Stable hydrogel compositions including additives
WO2016128783A1 (en) 2015-02-09 2016-08-18 Allergan Industrie Sas Compositions and methods for improving skin appearance
EA202190722A1 (en) * 2015-08-18 2021-10-29 Астеллас Инститьют Фор Ридженерэйтив Медсин CLINICAL COMPOSITIONS
HUE054874T2 (en) 2015-09-24 2021-10-28 Matrix Biology Inst High elasticity hyaluronan compositions and methods of use thereof
PL3525799T3 (en) * 2016-10-14 2022-05-16 i.com medical GmbH Method for establishing, restoring, and preserving homeostasis of the ocular surface
US20190151500A1 (en) * 2017-11-22 2019-05-23 Bausch & Lomb Incorporated Ophthalmic viscoelastic compositions
CN113354757B (en) * 2021-06-26 2022-04-08 上海加新生物科技有限公司 Preparation method of small molecule sodium hyaluronate

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4141973A (en) 1975-10-17 1979-02-27 Biotrics, Inc. Ultrapure hyaluronic acid and the use thereof
US5409904A (en) * 1984-11-13 1995-04-25 Alcon Laboratories, Inc. Hyaluronic acid compositions and methods
US4886786A (en) * 1985-08-01 1989-12-12 Lindstrom Richard L Additive for irrigation solution or surgical solution
IL80298A (en) 1986-10-14 1993-01-31 Res & Dev Co Ltd Eye drops
US4920104A (en) * 1988-05-16 1990-04-24 Medchem Products, Inc. Sodium hyaluronate composition
US5204331A (en) * 1990-06-29 1993-04-20 Santen Pharmaceutical Co., Ltd. Composition for debridement of retained lens materials
WO1994007505A1 (en) * 1991-07-03 1994-04-14 Norpharmco Inc. Use of hyaluronic acid and forms to prevent arterial restenosis
JPH06107538A (en) * 1992-03-31 1994-04-19 Shiseido Co Ltd Bulb of eye preserving solution for cornea graft
JPH05310580A (en) * 1992-04-30 1993-11-22 Shiseido Co Ltd Liquid preparation for entopic perfusion

Also Published As

Publication number Publication date
EP0781547A1 (en) 1997-07-02
ITMI952744A0 (en) 1995-12-22
ATE216221T1 (en) 2002-05-15
IT1277707B1 (en) 1997-11-11
DE69620724D1 (en) 2002-05-23
DK0781547T3 (en) 2002-08-12
ES2175020T3 (en) 2002-11-16
JP4146910B2 (en) 2008-09-10
CA2193543C (en) 2006-02-21
DE69620724T2 (en) 2002-11-21
US5880107A (en) 1999-03-09
ITMI952744A1 (en) 1997-06-22
EP0781547B1 (en) 2002-04-17
PT781547E (en) 2002-09-30
JPH09216826A (en) 1997-08-19

Similar Documents

Publication Publication Date Title
CA2193543A1 (en) Sodium hyaluronate based ophthalmic formulation for use in eye surgery
CA2282427A1 (en) Controlled release of pharmaceuticals in the anterior chamber of the eye
AU2824295A (en) Controlled vacuum in ophthalmic retinal surgery
CA2353835A1 (en) Composition set and kit for use in intraocular surgery
CA2436269A1 (en) Artificial tear composition containing a combination of three demulcents
MX9702349A (en) Use of 9-deoxy prostaglandin derivatives to treat glaucoma.
IE893270L (en) Ophthalmic staple and instruments for implementing use
CA2361827A1 (en) Multifocal ophthalmic lens with reduced halo size
AU5318394A (en) Eye stabilizing mechanism for use in ophthalmic laser surgery
CA2159055A1 (en) Compositions containing polyanionic polysaccharides and hydrophobic bioabsorbable polymers
AUPP697398A0 (en) Eye tracker for refractive surgery
AU6628496A (en) Polyether block copolymer micellar compositions for targeting biological agents
CA2265767A1 (en) Stable pharmaceutical composition including 4,5-epoxy-morphinan derivative
CA2295061A1 (en) Storage-stable ophthalmic compositions comprising diclofenac and ofloxacin
AU7702291A (en) Dietary fiber, its process and physiologically active composition containing the same as an active ingredient
AU6434998A (en) Oral composition exhibiting enhance uptake
AU633754B2 (en) Composition for eye drops
WO2000018316A3 (en) Sustained release, and comfortable ophthalmic composition and method for ocular therapy
CA2154103A1 (en) Treatment of Mucous Membrane Disease, Trauma or Condition and for the Relief of Pain
CA2282757A1 (en) Opthalmic composition
WO1998039293A3 (en) 13-thia prostaglandins for use in glaucoma therapy
AU3658793A (en) Bimodal molecular weight hyaluronate formulations and methods for using same
CA2063273A1 (en) Surfactant compositions and methods
CA2152998A1 (en) Anti-hyperglycemia pharmaceutical composition
CA2307303A1 (en) Prolonged-action eye drop

Legal Events

Date Code Title Description
EEER Examination request
MKEX Expiry

Effective date: 20161220